Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.
|Number of pages||2|
|Journal||Asian Journal of Pharmaceutical and Clinical Research|
|Publication status||Published - 01-04-2017|
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
- Pharmacology (medical)